The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature

Jacob Weber, Ali Olyaei, Joseph Shatzel

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

Direct oral anticoagulants (DOACs) have been shown to be superior to vitamin K antagonists (VKAs) in regards to safety and efficacy in numerous clinical trials and are now the preferred oral anticoagulant by multiple professional societies. However, patients with significant levels of organ dysfunction were excluded from all major clinical trials, leaving the clinical benefit in these subsets uncertain. Patients with chronic kidney disease (CKD) specifically often require anticoagulation for acute or long-term indications such as venous thromboembolism, atrial fibrillation, or mechanical heart valves. The efficacy and safety of anticoagulation in patients with renal failure is less certain, however, particularly with DOACs which have altered pharmacokinetics in patients with renal failure and limited observational data on their use in this population. In this review, we compile the most up to date data on the DOAC use in patients with CKD. DOAC use in patients with ESRD and advanced CKD is increasing despite the presence of a clear benefit, and with the potential for increased risk of bleeding compared to warfarin. Apixaban has the greatest amount of outcomes research supporting its use over warfarin in this patient population; however, further research on DOAC safety and efficacy in those with advanced CKD is still needed.

Original languageEnglish (US)
Pages (from-to)312-318
Number of pages7
JournalEuropean Journal of Haematology
Volume102
Issue number4
DOIs
StatePublished - Apr 2019

Keywords

  • clinical trials
  • coagulation disorders

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature'. Together they form a unique fingerprint.

Cite this